이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

APOE4/4 조기 알츠하이머 환자에서 ALZ-801의 효능 및 안전성 연구 (APOLLOE4)

2026년 9월 3일 업데이트: Alzheon Inc.

초기 알츠하이머병 및 APOE4/4 유전자형을 가진 피험자에서 ALZ-801의 효능, 안전성 및 바이오마커 효과에 대한 3상, 다기관, 무작위, 이중맹검, 위약 대조 연구

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

연구 개요

상세 설명

This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.

연구 유형

중재적

등록 (실제)

325

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • 's-Hertogenbosch, 네덜란드, 5223 LA
        • Brain Research Center Den Bosch
      • Amsterdam, 네덜란드, 1081 GN
        • Brain Research Center Amsterdam
      • Zwolle, 네덜란드, 8025 AZ
        • Brain Research Center Zwolle
      • Aachen, 독일, 52074
        • University Hospital RWTH Aachen Neurological Study Center
      • München, 독일, 80336
        • Klinikum der Universitaet Muenchen Innenstadt
      • Tübingen, 독일, 72076
        • Universitätsklinik fuer Psychiatrie und Psychotherapie
      • Westerstede, 독일, 26655
        • Studienzentrum Nord-West
    • Arizona
      • Phoenix, Arizona, 미국, 85004
        • Xenoscience
      • Scottsdale, Arizona, 미국, 85297
        • CCT Research
      • Sun City, Arizona, 미국, 85351
        • Banner Sun Health Research Institute
    • California
      • Costa Mesa, California, 미국, 92626
        • ATP Clinical Research
      • Irvine, California, 미국, 92780
        • Tilda Research
      • La Jolla, California, 미국, 92037
        • UCSD Shiley-Marcos Alzheimer's Disease Research Center
      • Lomita, California, 미국, 90717
        • Torrance Clinical Research Institute
      • Long Beach, California, 미국, 90806
        • Collaborative NeuroScience Network LLC
      • Palo Alto, California, 미국, 94304
        • Stanford University
      • Pasadena, California, 미국, 91105
        • SC3 Research Group
      • Sacramento, California, 미국, 95816
        • Sutter Health
    • Florida
      • Atlantis, Florida, 미국, 33462
        • JEM Research Institute, Headlands Site
      • Bradenton, Florida, 미국, 34205
        • Bradenton Research Center
      • Hialeah, Florida, 미국, 33016
        • Galiz Research
      • Jupiter, Florida, 미국, 33458
        • Alphab Global Research
      • Lady Lake, Florida, 미국, 32159
        • Charter Research
      • Maitland, Florida, 미국, 32751
        • K2 Medical Research, LLC
      • Miami, Florida, 미국, 33137
        • Miami Jewish Health
      • Miami, Florida, 미국, 33144
        • Y & L Advance Health Care, Inc /DBA Elite Clinical Research
      • Miami Beach, Florida, 미국, 33140
        • Mount Sinai Medical Center
      • Naples, Florida, 미국, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, 미국, 32819
        • Headlands Research Orlando
      • Orlando, Florida, 미국, 32803
        • Charter Research
      • Palm Beach Gardens, Florida, 미국, 33410
        • Advanced Research Consultants
      • Pompano Beach, Florida, 미국, 33064
        • Quantum CNS Clinical Research
      • Port Orange, Florida, 미국, 32127
        • Progressive Medical Research
      • Stuart, Florida, 미국, 34997
        • ALZ Research and Treatment Center (A.R.T.C.)
      • Wellington, Florida, 미국, 33414
        • ALZ Research and Treatment Center (A.R.T.C.)
      • West Palm Beach, Florida, 미국, 33407
        • Premiere Research Institute
    • Georgia
      • Columbus, Georgia, 미국, 31909
        • Columbus Memory Center
      • Decatur, Georgia, 미국, 30030
        • Sandhill Research, LLC
    • Indiana
      • Fort Wayne, Indiana, 미국, 46804
        • Fort Wayne Neurological Center
    • Louisiana
      • Shreveport, Louisiana, 미국, 71103
        • Louisiana State University Health Sciences Center (LSUHSC)
    • Massachusetts
      • Plymouth, Massachusetts, 미국, 02360
        • Headlands Research Eastern MA
    • Nevada
      • Las Vegas, Nevada, 미국, 89106
        • WR-CRCN
    • New Jersey
      • Toms River, New Jersey, 미국, 08755
        • Advanced Memory Research Center
    • New York
      • Albany, New York, 미국, 12208
        • Neurological Associates of Albany
      • New York, New York, 미국, 10016
        • NYU Alzheimer's Disease Research Center
      • Orangeburg, New York, 미국, 10962
        • Kline Institute for Psychiatric Research
      • Rochester, New York, 미국, 14620
        • University of Rochester Medical Center
      • Staten Island, New York, 미국, 10312
        • Richmond Behavioral Associates
    • North Carolina
      • Greensboro, North Carolina, 미국, 27410
        • Triad Clinical Trials
      • Matthews, North Carolina, 미국, 28105
        • AMC Research
    • Ohio
      • Canton, Ohio, 미국, 44718
        • NeuroScience Research Center
      • Dayton, Ohio, 미국, 45459
        • Neurology Diagnostics, Inc.
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73106
        • IPS Research
    • Oregon
      • Portland, Oregon, 미국, 97225
        • Center for Cognitive Health
    • Pennsylvania
      • Abington, Pennsylvania, 미국, 19001
        • Abington Neurological Associates
      • Allentown, Pennsylvania, 미국, 18104
        • Lehigh Center for Clinical Research
    • Rhode Island
      • East Providence, Rhode Island, 미국, 02914
        • Rhode Island Mood & Memory Research Institute
    • Tennessee
      • Nashville, Tennessee, 미국, 37212
        • Vanderbilt Center for Cognitive Medicine
    • Texas
      • Houston, Texas, 미국, 77054
        • UT Health Science Center at Houston
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Re:Cognition Health
    • Washington
      • Bellevue, Washington, 미국, 98007
        • Northwest Clinical Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin
      • Barcelona, 스페인, 08028
        • Fundacia ACE - Institut Catala de Neurociencies Aplicadas
      • Madrid, 스페인, 28040
        • Hospital Clinico San Carlos
      • Madrid, 스페인, 28027
        • Clinica Universidad de Navarra
      • Pamplona, 스페인, 31008
        • Clinica Universidad de Navarra
      • Terrassa, 스페인, 08221
        • Hospital Universitari MutuaTerrassa
      • Valencia, 스페인, 46017
        • Centro Hospital Universitario Dr. Preset
      • Reykjavik, 아이슬란드, 101
        • Memory Clinic, Landspitali University Hospital
      • Bristol, 영국, BS32 4SY
        • Re:Cognition Health Ltd Bristol
      • London, 영국, EC2Y 8EA
        • St. Pancras Clinical Research
      • Winchester, 영국, SO21 1HU
        • Re-Cognition Health Ltd Winchester
    • Devon
      • Plymouth, Devon, 영국, PL6 8BT
        • Re-Cognition Health Ltd Plymouth
    • Greater London
      • London, Greater London, 영국, W1G 9JF
        • Re-Cognition Health Ltd London
    • North Lanarkshire
      • Motherwell, North Lanarkshire, 영국, ML1 4UF
        • NeuroClin Glasgow Ltd
    • Surrey
      • Guildford, Surrey, 영국, GU2 7YD
        • Re-Cognition Health Ltd Guildford
    • West Midlands
      • Birmingham, West Midlands, 영국, B16 8LT
        • Re-Cognition Health Ltd Birmingham
      • Brno, 체코, 656 91
        • Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
      • Brno, 체코, 602 00
        • Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
      • Prague, 체코, 160 00
        • Neuropsychiatrie s.r.o.
      • Rychnov nad Kněžnou, 체코, 51601
        • Vestra Clinics - Dedicated Research Clinics
    • British Columbia
      • Kelowna, British Columbia, 캐나다, V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3S 1N2
        • Centricity Research
      • New Minas, Nova Scotia, 캐나다, B4N 3R7
        • Centricity Research
    • Ontario
      • Ottawa, Ontario, 캐나다, K1Z 1G3
        • Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
      • Peterborough, Ontario, 캐나다, K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto, Ontario, 캐나다, M3B 2S7
        • Toronto Memory Program
    • Quebec
      • Gatineau, Quebec, 캐나다, J8T 8J1
        • Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
      • Marseille, 프랑스, 13385
        • Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
      • Montpellier, 프랑스, 43431
        • Hopital Gui de Chauliac - CHRU de Montpellier
      • Paris, 프랑스, 75475
        • Hopital Lariboisiere - Fernand-Widal - AP-HP
      • Rouen, 프랑스, 76031
        • Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
      • Strasbourg, 프랑스, 67200
        • Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
      • Toulouse, 프랑스, 31059
        • Centre de Recherche Clinique du Gerontopole - CHU Toulouse
      • Villeurbanne, 프랑스, 69100
        • Centre de Recherche-Hopital Geriatrique de Charpennes

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
  • Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
  • MMSE score at Screening of 22 to 30 (inclusive).
  • CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
  • RBANS delayed memory index score ≤ 85.
  • Evidence of progressive memory loss over the last 12 months per investigator assessment

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
  • Diagnosis of neurodegenerative disorder other than AD.
  • Diagnosis of major depressive disorder (MDD) within one year prior to screening.
  • Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
  • History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
  • History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
  • Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ALZ-801

ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID).

ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID

다른 이름들:
  • Valiltramiprosate
  • 트라 미트로 세이트 전구 약물

Placebo tablet BID

위약 비교기: Placebo

Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study

Placebo tablet BID

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
기간: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
기간: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal.

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

2차 결과 측정

결과 측정
측정값 설명
기간
Key Secondary Endpoint (A-IADL-W)
기간: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
Key Secondary Endpoint (CDR-SB)
기간: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD)
기간: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE)
기간: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78

기타 결과 측정

결과 측정
측정값 설명
기간
Imaging Biomarker Endpoint (Hippocampal Volume)
기간: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe.

Baseline to Week 78
Imaging Biomarker Endpoint (Whole Brain Volume)
기간: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint (Ventricular Volume)
기간: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
기간: Baseline to Week 78

Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
기간: Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
기간: Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
기간: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
기간: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - MCI Subgroup
기간: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Mild AD Subgroup
기간: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - MCI Subgroup
기간: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Mild AD Subgroup
기간: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - MCI Subgroup
기간: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Mild AD Subgroup
기간: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE) - MCI Subgroup
기간: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Global Cognition Assessment (MMSE) - Mild AD Subgroup
기간: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Hippocampal Volume (MCI Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Hippocampal Volume (Mild AD Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (MCI Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Mayo Index) (MCI Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Whole Brain Volume (MCI Subgroup)
기간: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Whole Brain Volume (Mild AD Subgroup)
기간: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (MCI Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (Mild AD Subgroup)
기간: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
기간: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
기간: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - Female Subgroup
기간: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Male Subgroup
기간: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - Female Subgroup
기간: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Male Subgroup
기간: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - Female Subgroup
기간: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Male Subgroup
기간: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Treatment Emergent Adverse Events (TEAE) - Females
기간: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
Treatment Emergent Adverse Events (TEAE) - Males
기간: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Susan Abushakra, MD, Alzheon Inc.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 19일

기본 완료 (실제)

2024년 5월 29일

연구 완료 (실제)

2024년 7월 29일

연구 등록 날짜

최초 제출

2021년 2월 22일

QC 기준을 충족하는 최초 제출

2021년 2월 22일

처음 게시됨 (실제)

2021년 2월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 3일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ALZ-801-AD301
  • R01AG065253 (미국 NIH 보조금/계약)
  • 2020-005755-20 (EudraCT 번호)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다